Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-23 am EDT 		5-day change 1st Jan Change
4,134 JPY +0.78% Intraday chart for Takeda Pharmaceutical Company Limited -0.60% +1.97%
May. 16 Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment MT
May. 15 Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TAKEDA PHARMACEUTICAL : Form 6-K
PU
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment
MT
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
AQ
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification
MT
FDA extends review of Ascendis Pharma's hormone disorder therapy
RE
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
MT
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
MT
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
BU
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Gainers
MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate
MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda
DJ
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
BU
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement
AQ
Takeda Pharmaceutical, Announces full-year 2023 results and outlook for 2024 Emphasizes commitment to late-stage pipeline development and core operating margin improvement
AQ
Takeda Pharmaceutical's Attributable Profit Falls 55% in Fiscal 2024
MT
Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup
DJ
Sector Update: Health Care Stocks Steady Pre-Bell Thursday
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited